Enanta Pharmaceuticals (ENTA) Operating Leases (2019 - 2026)

Enanta Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $52.8 million for Q1 2026.

• Quarterly Operating Leases fell 6.65% year-over-year to $52.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.8 million (down 6.65% YoY) and the FY2025 annual result came in at $54.8 million, up 1.51% from the prior year.
• Operating Leases was $52.8 million for Q1 2026 at Enanta Pharmaceuticals, down from $53.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $56.5 million in Q1 2025 and bottomed at $15.1 million in Q1 2022.
• A 5-year average of $37.9 million and a median of $43.4 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases surged 1886.86% — and 2026, when it retreated 6.65%.
• Enanta Pharmaceuticals' Operating Leases stood at $21.9 million in 2022, then slipped by 6.11% to $20.5 million in 2023, then surged by 175.06% to $56.5 million in 2024, then slipped by 4.73% to $53.8 million in 2025, then fell by 1.87% to $52.8 million in 2026.
• Business Quant data shows ENTA's Operating Leases at $52.8 million in Q1 2026, $53.8 million in Q4 2025, and $54.8 million in Q3 2025.